Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone415-429-7800
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees76
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Tricida (NASDAQ:TCDA) Frequently Asked Questions
What is Tricida's stock symbol?
Tricida trades on the NASDAQ under the ticker symbol "TCDA."
How were Tricida's earnings last quarter?
Tricida Inc (NASDAQ:TCDA) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.75) EPS for the quarter, topping the Zacks' consensus estimate of ($0.87) by $0.12. View Tricida's Earnings History.
When is Tricida's next earnings date?
What price target have analysts set for TCDA?
3 brokers have issued twelve-month price targets for Tricida's stock. Their predictions range from $48.00 to $58.00. On average, they expect Tricida's stock price to reach $51.50 in the next year. This suggests a possible upside of 43.2% from the stock's current price. View Analyst Price Targets for Tricida.
What is the consensus analysts' recommendation for Tricida?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tricida.
Has Tricida been receiving favorable news coverage?
Headlines about TCDA stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Tricida earned a media sentiment score of -2.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Tricida.
Who are some of Tricida's key competitors?
Some companies that are related to Tricida include Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Dr.Reddy's Laboratories (RDY), Beigene (BGNE), ACADIA Pharmaceuticals (ACAD), Amarin (AMRN), Reata Pharmaceuticals (RETA), Horizon Therapeutics (HZNP), The Medicines (MDCO), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), GW Pharmaceuticals PLC- (GWPH), United Therapeutics (UTHR) and Arrowhead Pharmaceuticals (ARWR).
What other stocks do shareholders of Tricida own?
Who are Tricida's key executives?
Tricida's management team includes the folowing people:
- Dr. Gerrit Klaerner, Founder, Pres, CEO & Exec. Director (Age 48)
- Mr. Geoffrey M. Parker, CFO & Sr. VP (Age 54)
- Dr. Dawn Parsell Ph.D., Sr. VP of Clinical Devel. (Age 57)
- Steffen Pietzke, VP of Fin. & Chief Accounting Officer
- Dr. Wilhelm Stahl, CTO & Sr. VP (Age 59)
When did Tricida IPO?
(TCDA) raised $175 million in an initial public offering on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.
Who are Tricida's major shareholders?
Tricida's stock is owned by a number of of retail and institutional investors. Top institutional investors include Nisa Investment Advisors LLC (0.01%) and Zurcher Kantonalbank Zurich Cantonalbank (0.00%). Company insiders that own Tricida stock include Beek Jeroen B Van, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Robert J Alpern, Sandra I Coufal, Steffen Pietzke and Wilhelm Stahl. View Institutional Ownership Trends for Tricida.
Which major investors are buying Tricida stock?
TCDA stock was purchased by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Tricida stock in the last two years include Beek Jeroen B Van, Edward J Hejlek, Geoffrey M Parker, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Sandra I Coufal and Steffen Pietzke. View Insider Buying and Selling for Tricida.
How do I buy shares of Tricida?
Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Tricida's stock price today?
One share of TCDA stock can currently be purchased for approximately $35.96.
How big of a company is Tricida?
Tricida has a market capitalization of $1.78 billion. The company earns $-102,810,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis. Tricida employs 76 workers across the globe.View Additional Information About Tricida.
What is Tricida's official website?
How can I contact Tricida?
Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]
MarketBeat Community Rating for Tricida (NASDAQ TCDA)
MarketBeat's community ratings are surveys of what our community members think about Tricida and other stocks. Vote "Outperform" if you believe TCDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TCDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
